Accolade ( NASDAQ:ACCD ) First Quarter 2025 Results Key Financial Results Revenue: US$110.5m (up 19% from 1Q 2024). Net...
Accolade stock was falling sharply after its earnings report disappointed. Analyst Jack Wallace lowered his price target on the tech and health company to $6 from $13, while maintaining a Buy rating on the stock. Wallace added the optimism was fueled by his belief that the stock’s valuation is at a bottom, and management’s lowering of its fiscal-year guidance is a “clearing of the decks move that should allow ACCD to at least meet, if not exceed, guidance for the rest of the year.”
Accolade, Inc. (NASDAQ:ACCD) Q1 2025 Earnings Call Transcript June 27, 2024 Accolade, Inc. beats earnings expectations. Reported EPS is $-0.35, expectations were $-0.48. Operator: Hello, and thank you for standing by. Welcome to the Accolade First Quarter 2025 Earnings Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ […]